Atorvastatin negatively regulates MAPK pathway in vitro to inhibit proliferation, migration, and invasion of hepatocellular carcinoma cells.

ABSTRACT: Hepatocellular carcinoma (HCC) is a prevalent type of tumor. Given the controversy surrounding atorvastatin and HCC, we conducted this study to determine whether atorvastatin has anticancer activity against HCC. The impact of varying concentrations of atorvastatin (ATO) on the biological function of HCC cells was studied in vitro, high-throughput mRNA assays on cells and tumor tissue. Finally, an examination was conducted to assess the correlation between the ATO and the prognosis of HCC. ATO significantly inhibited the proliferation, migration, and invasiveness of HCC cells. Furthermore, in vivo, animal experiments showed that a high-fat diet facilitated the progression of HCC and that ATO did not effectively counteract these detrimental consequences. Tumor sequencing of cells and normal

SUBMITTER: Meng Y 

PROVIDER: S-EPMC12639006 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature